Last updated: September 13, 2026
Elagolix sodium is a nonpeptide gonadotropin-releasing hormone antagonist marketed by AbbVie as Orilissa for endometriosis-associated pain and as Oriahnn, in combination with estradiol and norethindrone acetate, for heavy menstrual bleeding associated with uterine fibroids. The U.S. market has shifted from launch expansion to lifecycle management. Revenue growth depends on diagnosis, duration limits caused by bone mineral density loss, reimbursement, and the timing of generic entry.
Orilissa remains the principal commercial product. Oriahnn has a narrower indication and more complex dosing, which limits its market scale. Elagolix is a small molecule, so biosimilar competition is not relevant. Generic risk is the main long-term exclusivity issue.
What is elagolix sodium and which products contain it?
Elagolix sodium is an orally administered GnRH receptor antagonist. It suppresses luteinizing hormone and follicle-stimulating hormone secretion, reducing ovarian estradiol and progesterone production.
| Product |
Active ingredients |
FDA indication |
Initial FDA approval |
Manufacturer |
| Orilissa |
Elagolix sodium |
Moderate-to-severe pain associated with endometriosis |
July 24, 2018 |
AbbVie |
| Oriahnn |
Elagolix sodium, estradiol, norethindrone acetate |
Heavy menstrual bleeding associated with uterine leiomyomas |
May 29, 2020 |
AbbVie |
Orilissa is supplied in two regimens:
- 150 mg once daily, generally limited to 24 months.
- 200 mg twice daily, generally limited to six months because of greater bone-loss risk.
Oriahnn is supplied as a co-packaged regimen:
- Morning capsule: elagolix 300 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg.
- Evening capsule: elagolix 300 mg.
- Treatment is generally limited to 24 months.
The duration restrictions reduce lifetime revenue per patient. They also create demand for repeat treatment, alternative hormonal products, surgery, and other medical management.
How large is the elagolix market and what drives demand?
The commercial market is concentrated in the United States because Orilissa and Oriahnn have been primarily commercialized through AbbVie’s U.S. women’s-health portfolio. The main demand drivers are:
- Increased diagnosis of endometriosis and uterine fibroids.
- Use of oral therapy before surgery or injectable GnRH therapy.
- Patient preference for oral treatment.
- Specialist prescribing by gynecologists.
- Coverage for endometriosis pain and fibroid-related bleeding.
The main constraints are treatment duration, side effects, monitoring requirements, and competition from established therapies.
Endometriosis market dynamics
Orilissa competes with:
- Combined oral contraceptives.
- Progestins, including norethindrone acetate and dienogest.
- Depot medroxyprogesterone.
- GnRH agonists such as leuprolide.
- The oral GnRH antagonist relugolix.
- Surgery and nonpharmacologic pain management.
Orilissa’s differentiation is oral, dose-dependent ovarian suppression without injections. Its limitations include vasomotor symptoms, mood-related adverse events, lipid changes, and bone mineral density loss.
Treatment duration is particularly important. A patient receiving the 200 mg twice-daily regimen may reach the labeled six-month limit quickly. That caps prescription volume unless physicians transition the patient to another therapy or later restart treatment under the label.
Uterine fibroid market dynamics
Oriahnn competes with:
- Oral contraceptives.
- Tranexamic acid.
- Levonorgestrel intrauterine systems.
- Progestins.
- Injectable GnRH agonists.
- Relugolix, estradiol, and norethindrone acetate combinations.
- Surgical procedures, including hysterectomy and myomectomy.
Oriahnn has a more complicated package than stand-alone elagolix because it requires separate morning and evening capsules. Its estrogen and progestin components add thromboembolic and hormonal safety considerations. These factors constrain broad primary-care adoption.
What is the financial trajectory for Orilissa and Oriahnn?
AbbVie does not consistently disclose Orilissa and Oriahnn as separate line items in its principal consolidated revenue tables. The company groups them within women’s-health or other product categories in certain filings. That limits independent verification of product-level revenue and makes third-party estimates less reliable than reported company totals.
The commercial trajectory has four phases:
| Phase |
Period |
Market characteristic |
| Launch |
2018-2019 |
Orilissa adoption built through specialist prescribing and payer access |
| Expansion |
2020-2021 |
Oriahnn added a fibroid indication; COVID-19 reduced some office-based diagnosis and treatment activity |
| Maturity |
2022-2024 |
Growth moderated as diagnosis, payer controls, duration limits, and competing oral therapies shaped demand |
| Pre-generic defense |
2025 onward |
Revenue depends on lifecycle management, contracting, and patent enforcement |
Orilissa is the more important revenue asset because it launched first, addresses a larger diagnosed treatment population, and does not require the fixed-dose estrogen/progestin combination used in Oriahnn.
Oriahnn contributes strategic lifecycle value but has lower commercial flexibility. It is not a simple substitute for Orilissa because the products have different indications, dosing, and labeling.
Revenue exposure to generic entry
The financial risk is concentrated in Orilissa because a generic version of elagolix for endometriosis could affect:
- New patient starts.
- Refill persistence.
- Payer formulary placement.
- Net price.
- Physician willingness to use branded therapy before surgery.
- AbbVie’s ability to use the product as an anchor for women’s-health contracting.
Oriahnn faces a different competitive risk. A manufacturer may first enter with generic elagolix tablets or a combination product rather than reproduce AbbVie’s full branded package. The commercial impact would depend on FDA approval of the same indication, dosage strengths, labeling, and combination presentation.
What patents protect elagolix sodium and Orilissa?
The elagolix patent estate includes composition-of-matter, formulation, dosing, and method-of-use protections. The practical value of each category differs.
| Patent category |
Protected subject matter |
Commercial relevance |
| Composition |
Elagolix and related GnRH antagonist compounds |
Historically the strongest barrier, but core claims may expire before later patents |
| Pharmaceutical composition |
Elagolix formulations, salts, dosage forms, and excipients |
Can delay or complicate generic approval |
| Method of treatment |
Treatment of endometriosis-associated pain and uterine fibroid bleeding |
Depends on FDA labeling and induced-infringement risk |
| Dosing regimen |
Low-dose and high-dose oral administration schedules |
Can support specific strengths and indications |
| Combination therapy |
Elagolix with estradiol and norethindrone acetate |
More relevant to Oriahnn |
| Manufacturing |
Processes for active ingredient or finished dosage forms |
Usually a secondary barrier unless process claims are difficult to design around |
The Orange Book is the controlling commercial reference for patents listed against FDA-approved products. Patent numbers, expiration dates, and listing status can change through corrections, delistings, terminal disclaimers, pediatric extensions, and litigation settlements. The most important analysis is product-specific: Orilissa patents should not be treated as automatically protecting Oriahnn, and vice versa.
Publicly reported patent disputes indicate that AbbVie has enforced later-issued patents covering elagolix products against generic applicants. The litigation strategy has focused on preserving the remaining commercial period after the five-year new chemical entity exclusivity period ended.
When does elagolix lose FDA exclusivity?
Elagolix’s regulatory exclusivity and patent exclusivity are separate.
FDA exclusivity
Orilissa received five-year new chemical entity exclusivity beginning with its July 2018 approval. That period generally prevented submission of an ANDA containing a Paragraph IV certification until 2023, subject to statutory exceptions.
Oriahnn received three-year exclusivity tied to the new clinical investigations supporting its 2020 approval. That exclusivity did not create a new five-year NCE period for elagolix because the active ingredient had already been approved in Orilissa.
Regulatory exclusivity does not establish the actual generic launch date. A generic may remain blocked by listed patents, a settlement agreement, pediatric exclusivity, or regulatory review timing.
Patent exclusivity
The principal commercial question is when listed patents expire and whether a generic applicant has obtained an earlier launch date through litigation or settlement. Public litigation reporting has pointed to generic challenges involving Orilissa patents and a potential launch window in the early 2030s rather than immediate post-exclusivity entry.
A precise commercial date requires reconciliation of:
- Current Orange Book listings.
- Patent expiration calculations.
- Patent term adjustment.
- Pediatric exclusivity.
- Paragraph IV litigation.
- Settlement terms.
- The scope of any generic approval.
How many patents cover Orilissa and Oriahnn?
The number varies by reference product, strength, Orange Book update, and whether expired or withdrawn patents are counted. A simple count can misstate the strength of the estate.
A useful assessment separates the estate into three layers:
- Core elagolix patents, which may cover the active ingredient or broad compound class.
- Product patents, which cover specific formulations, strengths, combinations, or delivery conditions.
- Use patents, which cover dosing regimens and disease-specific treatment.
A generic applicant can challenge every listed patent with a Paragraph IV certification, but the commercial effect depends on claim scope. A narrow method-of-use patent may not block a generic with a restricted label. A formulation patent may be avoided through a different excipient system. A composition patent is harder to design around but may expire earlier.
Which companies are challenging elagolix patents?
Generic companies have pursued or are expected to pursue elagolix through the ANDA pathway. Publicly reported litigation has included AbbVie patent enforcement against Teva-related generic activity concerning Orilissa patents.
The competitive field is likely to include:
- Large generic manufacturers with hormonal-product infrastructure.
- Companies experienced in Paragraph IV litigation.
- Contract manufacturers seeking ANDA partnerships.
- Combination-product developers targeting the fibroid market.
The absence of a public launch does not mean the patent estate is secure. ANDA litigation can resolve through settlement, license, dismissal, or a judgment that permits an earlier launch.
What patent litigation and settlement issues affect elagolix?
Elagolix litigation typically involves three questions:
Validity
Generic challengers may argue that claims are obvious, anticipated, inadequately described, or not enabled. Dose-regimen patents are often vulnerable to obviousness arguments when the underlying pharmacology and dose-response relationship are known.
Infringement
AbbVie must show that the generic product, labeling, manufacturing process, or intended use falls within asserted claims. A generic may narrow its label or exclude a patented indication under a section viii statement where permitted.
Remedy and launch timing
If AbbVie prevails, the court can impose a regulatory stay or injunction. If the parties settle, the settlement may establish a licensed entry date, royalty structure, or permitted product configuration.
Settlement terms are often confidential. A headline entry date may not apply to every strength or indication. It may also allow authorized generic supply or earlier entry under specified conditions.
What is the FDA and Orange Book status of elagolix?
Orilissa and Oriahnn are FDA-approved prescription products. They are small-molecule drugs approved under the NDA pathway. Generic applicants would use ANDAs and must demonstrate pharmaceutical equivalence and bioequivalence.
The relevant FDA framework includes:
- Orange Book patent listings.
- Paragraph IV certifications.
- Section viii statements for use patents where legally available.
- 30-month stays triggered by qualifying patent litigation.
- Therapeutic-equivalence ratings after approval.
- Product-specific guidance, where issued.
Because Oriahnn is a co-packaged combination with different morning and evening capsules, generic substitution may be more complex than for a single elagolix tablet. That complexity does not eliminate generic risk, but it may reduce the number of technically capable entrants.
How strong is the elagolix patent estate?
The estate is moderately strong commercially but not uniformly strong across all claim types.
| Factor |
Assessment |
| Active ingredient |
Strongest if valid, enforceable, and unexpired; exposure rises as core patents approach expiration |
| Orilissa dosing |
Potentially useful against indication-specific entry, but vulnerable to obviousness and label carve-outs |
| Oriahnn combination |
More difficult to reproduce exactly, but combination claims may face formulation and obviousness challenges |
| Manufacturing |
Relevant when process claims are narrow and difficult to design around |
| Patent layering |
Extends enforcement options but can increase invalidity exposure |
| Duration limits |
Commercial weakness because they limit patient-years of treatment |
| Generic technical barrier |
Moderate for Orilissa; higher for the Oriahnn co-packaged regimen |
Elagolix also faces a clinical patent weakness: bone-loss warnings and treatment-duration limits restrict the addressable duration of therapy. Patent protection cannot fully overcome a label that limits chronic use.
How does elagolix compare with relugolix?
| Attribute |
Elagolix |
Relugolix |
| Main brands |
Orilissa, Oriahnn |
Myfembree, Orgovyx |
| Key women’s-health uses |
Endometriosis pain; fibroid bleeding |
Endometriosis pain; fibroid bleeding |
| Administration |
Once daily or twice daily depending on product |
Generally once daily |
| Hormonal add-back |
Oriahnn includes estradiol/norethindrone |
Myfembree includes estradiol/norethindrone |
| Main commercial advantage |
Earlier market entry and established gynecology adoption |
Once-daily combination positioning and broader lifecycle strategy |
| Main risk |
Generic elagolix entry and duration limits |
Patent challenges and competition in oral GnRH therapy |
Relugolix has intensified competition in both endometriosis and uterine-fibroid treatment. The products compete on dosing convenience, payer access, safety monitoring, and physician familiarity rather than mechanism alone.
What generic launch scenarios exist for elagolix?
Three scenarios are commercially credible:
Early negotiated entry
AbbVie reaches a settlement with one or more generic applicants. Entry occurs before the last asserted patent expiration under a license. This scenario can preserve some branded revenue while creating a defined erosion date.
Single-indication entry
A generic enters for endometriosis under a label that omits a patented use or does not initially reproduce the Oriahnn combination. Orilissa revenue declines first, while Oriahnn remains protected by formulation, combination, or regulatory barriers.
Broad multi-product entry
Several generic companies obtain approvals covering elagolix strengths and the relevant indications. Net prices fall rapidly, payer substitution increases, and AbbVie’s revenue declines sharply after launch.
Generic erosion is usually faster for a simple tablet than for a co-packaged combination. Oriahnn may therefore experience a later or less concentrated loss of exclusivity than Orilissa, even if both products rely on the same active ingredient.
What geographic coverage and manufacturing barriers affect elagolix?
The commercial value of elagolix is concentrated in the United States. International opportunities are smaller because:
- Endometriosis and fibroid-treatment guidelines vary by country.
- Reimbursement differs substantially.
- Brand commercialization may not be consistent across jurisdictions.
- Patent families and supplementary protection rights differ by country.
- Local generic manufacturers may have different regulatory pathways.
Manufacturing barriers include control of elagolix active pharmaceutical ingredient, tablet crystallinity, salt form, impurity profile, bioequivalence, and the co-packaged Oriahnn presentation. These barriers can delay or reduce the number of entrants, but they are not equivalent to patent protection.
Key Takeaways
- Elagolix sodium is marketed as Orilissa for endometriosis and as Oriahnn for fibroid-related heavy menstrual bleeding.
- Orilissa is the primary commercial asset and the main source of generic-entry exposure.
- Oriahnn has greater product complexity but a narrower market and more difficult dosing presentation.
- Five-year NCE exclusivity for Orilissa began in 2018 and expired in the early 2020s; patent protection remains the central barrier.
- Publicly reported litigation indicates Paragraph IV challenges involving Orilissa patents, with commercial entry risks concentrated in the early 2030s.
- Bone mineral density loss and labeled treatment-duration limits restrict long-term patient value.
- Relugolix products are the principal branded oral GnRH-antagonist competitors.
- Biosimilar risk does not apply because elagolix is a small molecule.
- Revenue data are difficult to isolate because AbbVie does not consistently report Orilissa and Oriahnn as separate major consolidated line items.
- The strongest remaining defenses are product-specific formulation, combination, dosing, and method-of-use patents, not necessarily the original compound estate.
FAQs About Elagolix Sodium Patent and Market Risk
Is elagolix sodium a generic drug?
No. Elagolix sodium is the active ingredient in AbbVie’s branded products Orilissa and Oriahnn. Generic manufacturers may seek approval for equivalent products through the ANDA pathway.
Can generic elagolix substitute for Oriahnn?
Not automatically. Oriahnn is a co-packaged regimen containing elagolix, estradiol, and norethindrone acetate. A generic elagolix tablet alone would not be therapeutically equivalent to the full Oriahnn regimen.
Does elagolix have biosimilar competition?
No. Biosimilars apply to biologic products. Elagolix is a chemically synthesized small molecule and faces conventional generic competition.
What is the main commercial risk to Orilissa?
The main risk is generic entry after Orange Book-listed patents and related litigation are resolved. Additional risks include treatment-duration limits, payer restrictions, and competition from relugolix products.
Why is Oriahnn commercially different from Orilissa?
Oriahnn includes hormonal add-back therapy and uses separate morning and evening capsules for uterine fibroid bleeding. Orilissa is a stand-alone elagolix product for endometriosis-associated pain. Their indications, dosing, safety considerations, and substitution pathways differ.
References
- AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023.
- U.S. Food and Drug Administration. (2018, July 24). FDA approves new treatment for moderate to severe pain associated with endometriosis.
- U.S. Food and Drug Administration. (2020, May 29). FDA approves first oral medication for heavy menstrual bleeding due to uterine fibroids.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Orilissa (elagolix) and Oriahnn (elagolix, estradiol, and norethindrone acetate).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Approved labeling for Orilissa (elagolix tablets).
- U.S. Food and Drug Administration. (2024). Approved labeling for Oriahnn (elagolix, estradiol, and norethindrone acetate capsules).
